273 related articles for article (PubMed ID: 35705313)
1. Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study.
Tiu BC; Zubiri L; Iheke J; Pahalyants V; Theodosakis N; Ugwu-Dike P; Seo J; Tang K; Sise ME; Sullivan R; Naidoo J; Mooradian MJ; Semenov YR; Reynolds KL
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705313
[TBL] [Abstract][Full Text] [Related]
2. The association between the incidence risk of pneumonitis and PD-1/PD-L1 inhibitors in advanced NSCLC: A meta-analysis of randomized controlled trials.
Lin GF; Xu Y; Lin H; Yang DY; Chen L; Huang LL; Su XS; Xu YX; Zeng YM
Int Immunopharmacol; 2021 Oct; 99():108011. PubMed ID: 34426108
[TBL] [Abstract][Full Text] [Related]
3. Risk Factors for Immune Checkpoint Inhibitor-Related Pneumonitis in Cancer Patients: A Systemic Review and Meta-Analysis.
Zhou P; Zhao X; Wang G
Respiration; 2022; 101(11):1035-1050. PubMed ID: 36108598
[TBL] [Abstract][Full Text] [Related]
4. Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors.
Suresh K; Voong KR; Shankar B; Forde PM; Ettinger DS; Marrone KA; Kelly RJ; Hann CL; Levy B; Feliciano JL; Brahmer JR; Feller-Kopman D; Lerner AD; Lee H; Yarmus L; D'Alessio F; Hales RK; Lin CT; Psoter KJ; Danoff SK; Naidoo J
J Thorac Oncol; 2018 Dec; 13(12):1930-1939. PubMed ID: 30267842
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism.
Yin J; Wu Y; Yang X; Gan L; Xue J
Front Immunol; 2022; 13():830631. PubMed ID: 35464480
[TBL] [Abstract][Full Text] [Related]
6. Association of immune-related pneumonitis with clinical benefit of anti-programmed cell death-1 monotherapy in advanced non-small cell lung cancer.
Ono K; Ono H; Toi Y; Sugisaka J; Aso M; Saito R; Kawana S; Aiba T; Odaka T; Matsuda S; Saito S; Narumi A; Ogasawara T; Shimizu H; Domeki Y; Terayama K; Kawashima Y; Nakamura A; Yamanda S; Kimura Y; Honda Y; Sugawara S
Cancer Med; 2021 Jul; 10(14):4796-4804. PubMed ID: 34121358
[TBL] [Abstract][Full Text] [Related]
7. Tumor invasion in the central airway is a risk factor for early-onset checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer.
Moda M; Saito H; Kato T; Usui R; Kondo T; Nakahara Y; Murakami S; Yamamoto K; Yamada K
Thorac Cancer; 2020 Dec; 11(12):3576-3584. PubMed ID: 33078531
[TBL] [Abstract][Full Text] [Related]
8. Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy.
Suresh K; Psoter KJ; Voong KR; Shankar B; Forde PM; Ettinger DS; Marrone KA; Kelly RJ; Hann CL; Levy B; Feliciano JL; Brahmer JR; Feller-Kopman D; Lerner AD; Lee H; Yarmus L; Hales RK; D'Alessio F; Danoff SK; Naidoo J
J Thorac Oncol; 2019 Mar; 14(3):494-502. PubMed ID: 30503891
[TBL] [Abstract][Full Text] [Related]
9. High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer.
Tone M; Izumo T; Awano N; Kuse N; Inomata M; Jo T; Yoshimura H; Minami J; Takada K; Miyamoto S; Kunitoh H
Thorac Cancer; 2019 Oct; 10(10):2006-2012. PubMed ID: 31482678
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease.
Zeng Z; Qu J; Yao Y; Xu F; Lu S; Zhang P; Yao Y; Li N; Zhou J; Wang Y
BMC Pulm Med; 2022 Dec; 22(1):458. PubMed ID: 36456932
[TBL] [Abstract][Full Text] [Related]
11. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.
Khunger M; Rakshit S; Pasupuleti V; Hernandez AV; Mazzone P; Stevenson J; Pennell NA; Velcheti V
Chest; 2017 Aug; 152(2):271-281. PubMed ID: 28499515
[TBL] [Abstract][Full Text] [Related]
12. The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients.
Zhai X; Zhang J; Tian Y; Li J; Jing W; Guo H; Zhu H
Cancer Biol Med; 2020 Aug; 17(3):599-611. PubMed ID: 32944393
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study.
Fujimoto D; Miura S; Yoshimura K; Wakuda K; Oya Y; Yokoyama T; Yokoi T; Asao T; Tamiya M; Nakamura A; Yoshioka H; Haratani K; Teraoka S; Tokito T; Murakami S; Tamiya A; Itoh S; Yokouchi H; Watanabe S; Yamaguchi O; Tomii K; Yamamoto N
Eur J Cancer; 2021 Jun; 150():63-72. PubMed ID: 33892408
[TBL] [Abstract][Full Text] [Related]
14. Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis.
Huang A; Xu Y; Zang X; Wu C; Gao J; Sun X; Xie M; Ma X; Deng H; Song J; Ren F; Pang L; Qian J; Yu Z; Wan S; Chen Y; Pan L; Zhuang G; Liu S; Xue X
BMC Cancer; 2021 May; 21(1):634. PubMed ID: 34051746
[TBL] [Abstract][Full Text] [Related]
15. Recurrent and atypical immune checkpoint inhibitor-induced pneumonitis.
Jeon WJ; Nguyen J; Castillo DR; Park K; Brothers J; Nguyen A; Mirshahidi H
J Oncol Pharm Pract; 2023 Jul; 29(5):1264-1267. PubMed ID: 36648206
[TBL] [Abstract][Full Text] [Related]
16. Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer.
Cui P; Huang D; Wu Z; Tao H; Zhang S; Ma J; Liu Z; Wang J; Huang Z; Chen S; Zheng X; Hu Y
Ther Adv Med Oncol; 2020; 12():1758835920922033. PubMed ID: 32426052
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management.
Zhang Q; Tang L; Zhou Y; He W; Li W
Front Immunol; 2021; 12():663986. PubMed ID: 34122422
[TBL] [Abstract][Full Text] [Related]
18. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
19. Programmed cell death 1 (PD-1)/PD-ligand 1(PD-L1) inhibitors-related pneumonitis in patients with advanced non-small cell lung cancer.
Sun Y; Shao C; Li S; Xu Y; Xu K; Zhang Y; Huang H; Wang M; Xu Z
Asia Pac J Clin Oncol; 2020 Dec; 16(6):299-304. PubMed ID: 32757454
[TBL] [Abstract][Full Text] [Related]
20. Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials.
Wang M; Liang H; Wang W; Zhao S; Cai X; Zhao Y; Li C; Cheng B; Xiong S; Li J; He J; Liang W
Cancer; 2021 Mar; 127(5):777-786. PubMed ID: 33119182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
